The Future of JAK Inhibitors

Gilles de Prevoisin, Senior Consultant

Will JAK inhibitors triumph over persisting regulatory roadblocks to offer patients a new treatment option?

From blockbuster drugs to black box warnings, Janus kinase inhibitors (JAKs) have seen dramatic highs and lows in their journey to market access across the last few years. This innovative drug class has faced dizzying twists, turns and falls within the landscape of safety acceptability. Yet despite the hurdles JAKs are facing, pharma’s conviction in their potential to generate a paradigm shift in patient care means R&D activity and interest remains undaunted.

Driven by the sheer scale of the Immune-Mediated Inflammatory Diseases (IMIDs) treatment market and clear scenario of unmet patient need, the JAKs pipeline currently comprises no fewer than 45 therapeutic candidates. 1 In different stages of development, they are in a whole slew of IMID fields – and their journey is far from over.

JAK inhibitors are an oral class of therapeutics exciting to biopharma companies, investors, patients and physicians alike. Clinical results promise patients in multiple indications effective and more convenient treatment options. The first assets to enter the market, with approval for Rheumatoid Arthritis (RA), were tofacitinib (now also approved for Psoriatic Arthritis and Ulcerative Colitis) and baricitinib, followed by upadacitinib (RA).

First-generation JAKs have proven spectacularly efficacious both in clinical trials and in the clinic in treating inflammatory and autoimmune diseases – however, nearly all are facing an imbalance between safety and efficacy.

The result? JAKs’ rise in market success – for now – has hit unexpected turbulence.

Deallus JAK Inhibitors White Paper
DOWNLOAD WHITEPAPER

About the author

Gilles de Prevoisin Deallus Consultant

Gilles de Prevoisin

Gilles is a Senior Consultant at Deallus based in the Los Angeles office. His expertise range across different therapeutic areas, particularly rare diseases, gene therapy, respiratory diseases, inflammation and immunology, and diagnostics. Striving to establish his teams as valuable thought partners for clients, he brings a novel approach to delivering insights and analysis.

You may also be interested in…

  • Deallus Announce New Senior Principal

Gloria Kwon Joins Deallus as Senior Principal

We are excited to announce that Gloria Kwon has joined our Deallus team as a Senior Principal based out of our Los Angeles office. Gloria comes to Deallus with significant experience in business strategy, product commercialization and operational excellence for pharmaceutical and biotechnology companies. Prior to joining Deallus, Gloria spent over 8 years at Navigant Consulting.

  • Peter Barschdorff joins Deallus as Vice President (U.S.)

Peter Barschdorff joins Deallus as Vice President (U.S.)

Deallus is pleased to announce that Peter Barschdorff is joining the organization as Vice President, leading its U.S. consulting business, with offices in Los Angeles and New York. Peter has held leadership positions in a number of management consulting organizations and has built innovative enterprise capabilities in commercial pharma.

Deallus Keynote at Pharma CiMi.CON EU 2019

Jonas gives a keynote speech that delves into the importance of strategic intelligence for pharma given today’s dynamic and disruptive marketplace. He explores how competitive and strategic intelligence are related, how to build more strategically focused engagements, and how to help decision makers realize the value in strategic partnerships with their intelligence teams.